Post Profile

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK (Reuters) - Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.
read more


Related Posts

Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

Health : Medical News Today

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identif...

Array Biopharma Inc (ARRY), AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): This Cancer Biotech Is Looking for Other Green Pastures

Business & Finance / Investing : Insider Monkey

Array Biopharma Inc (NASDAQ:ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market. The company recently announced encouraging results – 6.8% improvement in FEV...

AstraZeneca wins early U.S. approval for blood cancer drug

Health : Reuters: Health

LONDON (Reuters) - AstraZeneca has won U.S. approval for a new blood cancer drug several months earlier than expected, boosting its oncology portfolio - and requiring it to pay $1.5 billion to shareholders in the biotech company tha...

Gilead sciences to pay Merck $2.54 billion in hepatitis c royalties: court verdict

Health : Reuters: Health

(Reuters) - A federal jury in Delaware on Thursday awarded Merck & Co $2.54 billion in royalties in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

FDA expands use of AstraZeneca/Merck ovarian cancer drug

Health : Reuters: Health

(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to pla...


Copyright © 2016 Regator, LLC